Phase 3Terminated
Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R)
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma
- Sponsor
- SecuraBio (Industry)
- Enrollment
- 13 enrolled
- Conditions
- Follicular Lymphoma
- Interventions
- Duvelisib; Placebo; Rituximab
- Ages
- adults, older adults
- Registry
- NCT02204982, EUCTR2013-002406-31
Full record on ClinicalTrials.gov
From the registry
A study to evaluate the safety and efficacy of duvelisib administered in combination with rituximab vs placebo in combination with rituximab in patients with previously treated CD20-positive follicular lymphoma who are not suitable candidates for chemotherapy.
Primary outcomes
- Progression-Free Survival (PFS)
History
Last registry update
Results first posted
Study completion
Primary completion
Started
Registered